In this article, we will take a detailed look at the Top 10 Trending Stocks to Watch Ahead of Nvidia Earnings.

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

On Friday, the U.S. District Court for the District of Maryland paused several parts of a health insurance exchange enrollment and eligibility rule that was set to take effect today. The court agreed ...

Gilead Sciences (($GILD)) announced an update on their ongoing clinical study. Gilead Sciences is currently conducting a Phase 3 clinical study ...

At Martha’s Vineyard, Touch Talks Wellness and BlackDoctor.org joined forces to host an urgent and deeply personal conversation on cancer disparities in the Black community. Powered by partnerships ...

The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Interius is working on a more efficient way to deliver CAR-T therapy to patients. Unlock Digital Access for unlimited access to Inquirer.com and The Inquirer App, plus 5 articles per month to gift to ...

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc. (NASDAQ:GILD) has received a favorable opinion from the European Medicines ...